184 related articles for article (PubMed ID: 17917671)
1. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.
Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
Mod Pathol; 2007 Dec; 20(12):1307-15. PubMed ID: 17917671
[TBL] [Abstract][Full Text] [Related]
2. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.
Gudlaugsson E; Skaland I; Undersrud E; Janssen EA; Søiland H; Baak JP
Mod Pathol; 2011 Apr; 24(4):502-11. PubMed ID: 21317878
[TBL] [Abstract][Full Text] [Related]
3. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.
Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
Breast Cancer Res Treat; 2009 Mar; 114(1):39-45. PubMed ID: 18373192
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
[TBL] [Abstract][Full Text] [Related]
5. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
6. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
[TBL] [Abstract][Full Text] [Related]
8. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
9. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer.
Skaland I; Janssen EA; Gudlaugsson E; Hui Ru Guo L; Baak JP
Cell Oncol; 2009; 31(4):261-71. PubMed ID: 19633363
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
12. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
[TBL] [Abstract][Full Text] [Related]
13. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer.
Janssen EA; Øvestad IT; Skaland I; Søiland H; Gudlaugsson E; Kjellevold KH; Nysted A; Søreide JA; Baak JP
Cell Oncol; 2009; 31(5):335-43. PubMed ID: 19759414
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA
J Clin Oncol; 2005 Sep; 23(25):5993-6001. PubMed ID: 16135467
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
Jonsdottir K; Assmus J; Slewa A; Gudlaugsson E; Skaland I; Baak JP; Janssen EA
PLoS One; 2014; 9(3):e90642. PubMed ID: 24599057
[TBL] [Abstract][Full Text] [Related]
16. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium.
Jannink I; van Diest PJ; Baak JP
Hum Pathol; 1995 Oct; 26(10):1086-92. PubMed ID: 7557941
[TBL] [Abstract][Full Text] [Related]
18. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
20. Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years.
Janssen EA; Søiland H; Skaland I; Gudlaugson E; Kjellevold KH; Nysted A; Søreide JA; Baak JP
Cell Oncol; 2007; 29(1):25-35. PubMed ID: 17429139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
